Precigen Inc Endpoints Webinar: State of the Union for Advanced Therapies Transcript
And precision value and health have been advancing clinical and drug development, manufacturing and commercialization for the regenerative medicine sector for the past 10 years. Having been a partner to over advanced therapy organizations, we understand the complexities to bring a cell and gene therapy to market. Since our last day at the union addressed that advanced therapy landscape has changed significantly. During today's panel, we will be hearing from various experts on their respective companies. their perspectives on some of the roadblocks and opportunities in the cell and gene therapy development and the future of the sector moving forward. Now I'll briefly introduce our panelists. Joining us today are Dan Kirby, Chief Commercial Officer, Orca Bio. Welcome, Dan. Deborah Phippard, Chief Scientific Officer at Precision for Medicine. Helen Sabzevari, President and CEO of Precigen. Devyn Smith, CEO of Arbor Bio and Chad Salisbury, Senior Vice President of Project Pharma. All right. Let's get this rolling. To start, I would love to hear from each one of our panelists on their respective
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
